Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 17, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions.
Key transaction details include:
- Transaction Date: October 16, 2007 (Notification date).
- Transaction Type: Notional increase in interests following dividend re-investment.
- Share Prices: GBP 12.55 per Ordinary share; $51.61 per Ordinary Share ADR.
- Dividend Reference: Dividend paid to shareholders on October 11, 2007.
Material Changes
The filing reports an increase in notional interests for various executives and directors. No material changes to the company's financial position, operations, or strategy are disclosed in this specific document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Important Facts for Investors to Verify
- Verify the vesting schedule and conditions for the Performance Share Plan to understand when notional dividends become payable.
- Confirm the total number of shares and ADRs held by the listed executives prior to this notional increase.
- Review the full dividend declaration details from October 11, 2007, to contextualize the re-investment amounts.
- Check subsequent filings for the actual vesting outcomes of the three-year measurement period referenced.